About Cytiva
Cytiva is a Healthcare company based in Sheffield (United Kingdom) founded in 1968. Life science software and research products are provided online. The company has 496 employees. Cytiva has completed 4 acquisitions, including Cevec Pharmaceuticals, GoSilico and Intermountain Life Sciences. Its chief executive, as recorded, is Emmanuel Ligner. Its website cytivalifesciences.com draws about 312 thousand monthly visits. Its Indian entity Hyclone Life Sciences Solutions India Private Limited reported revenue of ₹539 Cr. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Scientific Sourcing.
Company details
Cytiva was founded in 1968 and is headquartered in Sheffield, United Kingdom. Operations focus on an online platform where software and products for life sciences research are distributed. Solutions for biological research, clinical therapy diagnosis, and drug discovery are offered, including sequencing technologies and tools. Key products encompass Xcellerex APS for downstream processes, IN Carta SINAP microscopes for cell analysis, and DeltaVision imaging systems.
- Headquarters Sheffield, United Kingdom
- Employees 496
- SectorsHealthcare
- Website category Science and Education · Biology
- Email••••••••
- Phone•••• ••••
- Website cytivalifesciences.com
- Social LinkedIn X Facebook
- Legal Name Hyclone Life Sciences Solutions India Private Limited
- Date of Incorporation 01 Aug, 2019
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹539 Cr
FY 2025 · -13% YoY
- Indian entity net profit₹57.52 Cr
FY 2025 · 11% margin
- Indian entity EBITDA₹108 Cr
FY 2025 · 20% margin
- Latest Funding Round$23.63K (USD), Grant
Oct 2023
- Investors
- Employee Count496
- Investments & AcquisitionsCevec Pharmaceuticals
& 3 more
Associated legal entities of Cytiva
Cytiva operates through Hyclone Life Sciences Solutions India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hyclone Life Sciences Solutions India Private Limited CIN U24304KA2019PTC126720 | Active | 01 Aug 2019 | Bangalore, Karnataka | ₹539 Cr | 496 | 6 | View details |
Funding Insights of Cytiva
- Total Rounds 2
- Last Round Grant — $23,633
- First Round $21,806
(May 2019)
- Investors Count 1
All 2 funding rounds of Cytiva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $23,633 | Grant | – | – | |
| May 2019 | $21,806 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Cytiva
Cytiva has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Cytiva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Hyclone Life Sciences Solutions India Private Limited (Cytiva)
Hyclone Life Sciences Solutions India Private Limited is the primary company behind Cytiva. The board of Hyclone Life Sciences Solutions India Private Limited currently have 5 directors; the longest-serving is Amol Laxman Kulkarni, appointed in 2020. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Amol Laxman Kulkarni DIN 00449663 | Company Secretary | 06 Mar 2020 | 6 yrs 8 mo | Hyclone Life Sciences Solutions India Private Limited |
| James Benjamin DIN 08728877 | Director | 31 Mar 2020 | 6 yrs 7 mo | Hyclone Life Sciences Solutions India Private Limited |
| Satya Prasad Udandravu DIN 03343809 | Director | 14 Jun 2022 | 4 yrs 4 mo | Hyclone Life Sciences Solutions India Private Limited |
| Ramakrishna Panicker Manoj Kumar DIN 10644865 | Director | 05 Jun 2024 | 2 yrs 5 mo | Hyclone Life Sciences Solutions India Private Limited |
| Balasubramanian Narayanan Iyer DIN 10986431 | Director | 12 Mar 2025 | 1 yr 7 mo | Hyclone Life Sciences Solutions India Private Limited |
People of Cytiva
1 people are tracked at Cytiva (1 in leadership); the tracked headcount is 496.
| Name | Role | Group |
|---|---|---|
Emmanuel Ligner | CEO & President | Leadership |
Complete people profiles for Cytiva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Cytiva
Figures of Hyclone Life Sciences Solutions India Private Limited, the primary company behind Cytiva, for FY 2025. Revenue was ₹539 Cr (-13% year on year). Net profit was ₹57.52 Cr (11% margin). EBITDA was ₹108 Cr (20% margin). Revenue has grown at a compounded annual rate of +23% over three years and +34% over five years.
- ₹539 CrRevenue · FY 2025 · -13% YoY
- ₹57.52 CrNet profit · 11% margin
- ₹108 CrEBITDA · 20% margin
- ₹235 CrPaid-up capital
- 496Employees (provident fund records)
- +23%Revenue CAGR, 3 years
- +34%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Hyclone Life Sciences Solutions India Private Limited are on its company page.
Detailed financial statements for Cytiva
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cytiva
Cytiva has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cevec Pharmaceuticals, GoSilico and Intermountain Life Sciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system | cevec.com | Cologne, Germany | 2001 | Oct 2022 | •••• | |
Pharmaceutical-grade water is manufactured for industry use. | ilsgmp.com | West Jordan, United States | 2014 | Jun 2021 | •••• | |
Simulation software for in silico bioprocess development is provided. | gosilico.com | Karlsruhe, Germany | 2016 | Jun 2021 | •••• | |
Aseptic filling systems for injectable pharmaceuticals are developed. | vanrx.com | Burnaby, Canada | 2007 | Jan 2021 | •••• |
Complete acquisition details for Cytiva
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cytiva
7 dated milestones of Cytiva across 55 years, from founding to its latest funding, stage changes and deals.
- Founded Cytiva is founded.
- Funding First funding round of $22K.
- Acquisition Acquires VanrX Pharmasystems.
- Acquisition Acquires GoSilico.
- Acquisition Acquires Intermountain Life Sciences.
- Acquisition Acquires Cevec Pharmaceuticals.
- Funding Latest funding round, Grant, of $24K.
Web traffic of Cytiva
The website of Cytiva (cytivalifesciences.com) receives about 312.5K visits a month and ranks #148,975 among all websites worldwide, #9,589 in Biology.
- Monthly visits312.5K
▼ 2.5% vs previous month
- Unique visitors151.5K
per month
- Global rank#148,975
among all websites
- Category rank#9,589
Science and Education · Biology
- Bounce rate44%
- Pages per visit2.4
- Average visit1 min 46 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Cytiva. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cell.com | 100% | 5M | #14,619 | View details | |
shop.sartorius.com | shop.sartorius.com | 98% | #552,012 | – | |
| benchling.com | 98% | 1.4M | #36,159 | View details | |
| aldevron.com | 96% | 12.5K | #1,963,419 | View details | |
creative-biolabs.com | creative-biolabs.com | 95% | #348,062 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Cytiva
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Cytiva (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytiva
Complete news archive for Cytiva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cytiva
Cytiva was founded in 1968 and raised its 1st funding round 51 years after it was founded.
Cytiva is headquartered in Sheffield, United Kingdom. It is registered at Sheffield, England, United Kingdom.
Emmanuel Ligner is the CEO of Cytiva, as recorded in our data.
Cytiva has 496 employees.
The primary company behind Cytiva, Hyclone Life Sciences Solutions India Private Limited, reported revenue of ₹539 Cr for FY 2025, down 13% year on year.
Cytiva was founded in 1968 and is headquartered in Sheffield, United Kingdom. Operations focus on an online platform where software and products for life sciences research are distributed. Solutions for biological research, clinical therapy diagnosis, and drug discovery are offered, including sequencing technologies and tools. Key products encompass Xcellerex APS for downstream processes, IN Carta SINAP microscopes for cell analysis, and DeltaVision imaging systems.
Cytiva has made 4 acquisitions, including Cevec Pharmaceuticals, GoSilico, and Intermountain Life Sciences.
Cytiva has 1 investor. Key investors include European Union.
Cytiva operates through Hyclone Life Sciences Solutions India Private Limited.
The legal entities of Cytiva currently have 5 directors, including Satya Prasad Udandravu, James Benjamin, Ramakrishna Panicker Manoj Kumar and others.
The website of Cytiva receives about 312 thousand visits a month and ranks #148,975 among all websites worldwide.